| MONALISA for stochastic simulations of Petri net models of biochemical systems P Balazki, K Lindauer, J Einloft, J Ackermann, I Koch BMC bioinformatics 16, 1-11, 2015 | 31 | 2015 |
| A quantitative systems pharmacology kidney model of diabetes associated renal hyperfiltration and the effects of SGLT inhibitors P Balazki, S Schaller, T Eissing, T Lehr CPT: pharmacometrics & systems pharmacology 7 (12), 788-797, 2018 | 22 | 2018 |
| A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin P Balazki, S Schaller, T Eissing, T Lehr CPT: pharmacometrics & systems pharmacology 9 (6), 353-362, 2020 | 5 | 2020 |
| Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach S Schaller, FS Martins, P Balazki, S Böhm, J Baumgart, RA Hilger, ... British Journal of Clinical Pharmacology 88 (4), 1722-1734, 2022 | 3 | 2022 |
| Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling K Mehta, P Balazki, PH van der Graaf, T Guo, JG van Hasselt Clinical Pharmacokinetics, 1-12, 2024 | | 2024 |
| PERSONALIZATION OF THE INSULIN DOSE-RESPONSE RELATIONSHIP IN T2DM USING A PB-QSP MODEL OF T2DM AND INDIVIDUAL SAMPLING OF C-PEPTIDE LEVELS. P Balazki, S Schaller, T Lehr CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S16-S16, 2021 | | 2021 |
| A QUANTITATIVE SYSTEMS PHARMACOLOGY KIDNEY MODEL OF DIABETES ASSOCIATED RENAL HYPERFILTRATION AND THE EFFECTS OF SGLT INHIBITORS. P Balazki, S Schaller, T Eissing, T Lehr CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S30-S30, 2019 | | 2019 |
| Personalized management of diabetes for the titration of insulin during initiation of SGLT2i treatment P Balazki, S Schaller, T Eissing, T Lehr JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S93-S94, 2018 | | 2018 |
| Simulation mode of MonaLisa-Documentation P Balazki, J Einloft | | 2014 |
| Population Approach Group Europe Population Approach Group Europe P Balazki | | |
| A mechanistic model of gastric emptying of caloric liquids and solids P Balazki | | |
| Physiologically-based Pharmacokinetics/Pharmacodynamics model of dapagliflozin, an oral SGLT2 inhibitor P Balazki, V Woerle, S Schaller, T Eissing, T Lehr | | |
Stephan SchallerFounder & CEO, esqLABS GmbHVerified email at esqlabs.com
